Clinical Trial Update: Shuxuetong for Prevention of Recurrence in Acute Cerebrovascular Events With Embolism [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating Shuxuetong for prevention of recurrence after acute cerebrovascular events with embolism has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Embolic Stroke

Drugs mentioned

• Shuxuetong

Snippet

Sponsor: Beijing Tiantan Hospital | Conditions: Embolic Stroke | Phase 4 | Status: COMPLETED